Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.

Status: Recruiting

Protocol number: PP21029

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, double-blind, single ascending dose study to investigate the safety, tolerability, pharmacokinetics and effect on pharmacodynamic biomarkers of an intravenous infusion of R1671 in patients with mild, intermittent asymptomatic asthma

Brief summary: This 8 arm study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of R1671 or placebo in patients with mild, intermittent, asymptomatic asthma. Patients will be randomized to receive placebo or R1671, at a starting dose of 0.0015mg, by intravenous infusion; this dose will be escalated in subsequent groups of patients after a satisfactory assessment of the data from the previous dose. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals. Target sample size is 64.

Study phase: I

Study type: Interventional; Treatment; Randomized; Double Blind; Placebo; Parallel; Safety study

Condition: Asthma

Intervention type: Drug

Intervention name: R1671

Primary outcome: 1. AEs, laboratory parameters, vital signs, ECG. Time frame: Throughout study 2. Serum concentration of R1671, and serum pharmacokinetic parameters. Time frame: Throughout study

Key secondary outcomes: 1. Pharmacodynamic biomarker sampling; skin prick test. Time frame: At intervals during study

Inclusion criteria:

  • adult patients, 18-50 years of age;
  • mild, intermittent, asymptomatic asthma;
  • history of asthma for >=6 months;
  • non-smokers.

Exclusion criteria:

  • females of childbearing potential, or lactating;
  • history of immunologically medicated disease;
  • systemic antineoplastic or immunomodulatory treatment in past 6 months.

Gender: Males or Females

Age limits: Min: 18 Years Max: 50 Years

Accepts healthy volunteers: No

Anticipated start date: October, 2007

Trial registration date: 08/15/2007

Date last updated: 8/29/2008


Link to trial result

This trial is being conducted at the following locations:

United States

  • Little Rock, AR
  • Burbank, CA
  • Port Orange, FL
  • Madisonville, KY
  • North Dartmouth, MA

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply